Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$27.67M$27.67M−0.2% vs Q3 2015 Net Income-$30.72M-$30.72MN/M vs Q3 2015 EPS Diluted-$0.28-$0.28N/M vs Q3 2015 Operating Income-$29,518,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,023,000N/M Margins · derivedOperating margin-106.7%+19.4 pt vs Q3 2015
Net margin-111.0%+18.9 pt vs Q3 2015
ended Sep 30, 2017 · filed Nov 8, 2017 · 39 d after period end